Four years after the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) for unresectable pleural mesothelioma, long-term follow-up data from the CheckMate 743 trial continues to demonstrate sustained survival benefits compared to chemotherapy alone.
The CheckMate 743 Trial
The immunotherapy combination was approved on October 2, 2020, representing the first new FDA-approved treatment for mesothelioma in 16 years — since pemetrexed in 2004. The approval was based on CheckMate 743, a Phase 3 trial that showed median survival of 18.1 months with immunotherapy versus 14.1 months with chemotherapy alone.
What the Long-Term Data Shows
Extended follow-up data published in 2024 confirmed that these survival benefits are durable. Patients who initially responded to immunotherapy continue to show improved outcomes compared to historical chemotherapy-only controls. Importantly, immunotherapy has shown particular benefit for patients with sarcomatoid cell type, which historically has had the worst prognosis of the three mesothelioma cell types.
What This Means for Mesothelioma Patients
Treatment options for mesothelioma continue to expand. Multimodal approaches combining surgery, chemotherapy, and immunotherapy offer the best outcomes. Treatment at specialized mesothelioma centers provides access to the full range of options including clinical trials testing next-generation immunotherapy combinations.
Legal Implications
Improved survival means more patients have time to pursue legal claims during their lifetime. Under most state statutes of limitations, legal deadlines start at diagnosis. Patients who pursue legal action early can see cases resolved while they are living, ensuring they have control over how compensation is used. For families, timely legal action also preserves evidence and witness availability. If you or a loved one has been diagnosed with mesothelioma, do not delay consulting an experienced attorney — both treatment and legal representation benefit from early action.